Communiqués I-Mab

Actions

IMAB

US44975P1030

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
1,87 ^USD	-1,58 %		+7,47 %	-1,58 %

06/06	I-Mab nomme Phillip Dennis au poste de directeur médical	CI
05/06	I-Mab collabore avec Bristol-Myers pour évaluer le givastomig dans une étude de combinaison pour les cancers de l'estomac et de l'œsophage	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	PR
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23/05	AQ
I-Mab to Participate at the Jefferies Global Healthcare Conference	22/05	PR
I-MAB Filed 2023 Annual Report on Form 20-F	30/04	PR
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04	PR
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04	PR
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04	PU
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	08/02	AQ
I-Mab Announces Participation at Jefferies and Piper Conferences in November	06/11	PR
I-Mab - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy	03/11	AQ
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	01/11	PR
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	16/10/23	PR
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503	11/10/23	AQ
I Mab : Regains Global Rights to Lemzoparlimab - Form 6-K	22/09/23	PU
I-Mab Announces Upcoming Participation at September Conferences	05/09/23	PR
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates	18/08/23	AQ
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023	08/08/23	PR
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma	11/07/23	AQ
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC	05/07/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués I-Mab

Actions

IMAB

US44975P1030

Communiqués

Filtres